CDKN2A and pancreatic adenocarcinoma: Additionally, we found that low CDKN2A expression in tumors of 6 different types, including melanoma and pancreatic adenocarcinoma, correlated with a decreased SASP signature [18], further demonstrating the role of p16 in regulation of the SASP.